Comparing two treatments for high-risk bone cancer
Treatments studied
Part of Cancer clinical trials.
This study tests two treatments for high-risk osteosarcoma (a bone cancer). It compares mifamurtide plus standard treatment versus sorafenib plus standard treatment to see which is safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 5 and 30 years old.
- You have osteosarcoma that is confirmed by biopsy.
- Your osteosarcoma is considered high-risk (not cured with standard treatment).
- You are expected to live for at least 12 more weeks.
- You are able to swallow tablets.
- You agree to use effective contraception during the study and for 1 year after treatment (if you can have children).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether surufatinib combined with chemotherapy given before surgery can shrink osteosarcoma and improve outcomes. It may help by attacking the tumor from more than one angle before the main treatment step.
This early-phase study tests whether adding losartan to sunitinib can help control osteosarcoma that has returned or keeps growing after at least one prior treatment. It may help by targeting the cancer’s growth signals and blood supply, but the goal at this stage is mainly to check safety and find workable dosing.
This Phase 2 study tests whether regorafenib, given after your main treatments, can help keep high-grade bone sarcoma from coming back or progressing. It checks safety and whether this “maintenance” approach works better than best supportive care alone.
This trial tests a new drug called OMO-103, which targets a protein called Myc that helps cancer cells grow. It is for people with advanced osteosarcoma (bone cancer) that has worsened after standard chemotherapy. The drug is given intravenously (through a vein), and the study will check if it is safe and shrinks tumors.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This trial studies whether regorafenib given after first treatment helps patients with bone sarcoma stay in remission longer. It focuses on safety and whether the medicine can prevent the cancer from growing or returning.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.